Fosamax and Osteonecrosis of the Jaw: Causation, Risk, and What Studies Show

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Occupational Exposure Concerns

Legacy health information resources have long served as trusted repositories for general wellness guidance, offering broad overviews of conditions and preventive measures. Within this tradition, the topic of medication safety has been addressed through population-level summaries, emphasizing adherence to prescribing guidelines and routine monitoring. However, the transition from general health communication to a focused occupational exposure concern requires a deliberate shift in perspective. In the context of mass production environments—where workers may handle raw materials, finished pharmaceuticals, or manufacturing byproducts—the relevance of specific drug-related risks becomes more acute. The legacy framework of general health information, while valuable for public awareness, does not typically account for the sustained, repeated, or concentrated exposures that can occur in industrial settings. This gap becomes particularly salient when considering agents such as bisphosphonates, where the pathway from therapeutic use to unintended occupational contact warrants careful examination.

Bridging to Fosamax and Osteonecrosis of the Jaw

The pivot from a general health context to an occupational exposure concern involves reframing the question: rather than asking about patient-level risk during prescribed use, the inquiry shifts to potential exposure scenarios for personnel involved in production, packaging, or waste management. This transition acknowledges that the same compound, when encountered outside the clinical setting, may present distinct risk profiles that legacy health summaries are not designed to address. Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a recognized adverse effect associated with bisphosphonate use, including Fosamax and Fosamax Plus D (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Clinical Presentation and Mechanistic Pathways

ONJ can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The clinical presentation of ONJ involves exposed necrotic bone in the jaw, often following dental procedures, and may be accompanied by pain, swelling, or infection. Diagnosis is based on clinical examination and imaging, with a focus on ruling out other causes of jaw necrosis. The mechanistic pathways linking Fosamax to ONJ involve the drug's potent inhibition of osteoclast-mediated bone resorption, which can suppress normal bone turnover and remodeling. This suppression, particularly in the jawbone, may impair healing after dental trauma or infection, leading to avascular necrosis. A multiscale characterization of jawbone has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research highlights the unique structural and cellular properties of the jaw that may predispose it to ONJ under bisphosphonate therapy.

Risk Factors and Epidemiological Evidence

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a known adverse effect, its incidence in clinical trials was not significantly elevated compared to placebo, likely due to the rarity of the condition. A cohort study among cancer-free female patients aged 40-89 with, or at risk for, osteoporosis in the United Kingdom Clinical Practice Research Datalink (CPRD Aurum) found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This study provides a quantitative assessment of the risk timeline, showing that longer exposure to bisphosphonates is associated with increased ONJ risk, but the absolute risk remains low in the osteoporosis treatment population.

Causation Assessment and Clinical Management

For affected patients, causation-focused clinical interpretation requires considering the temporal relationship between Fosamax exposure and ONJ onset, the presence of known risk factors (especially dental procedures), and the exclusion of other causes. The evidence supports a causal link, as ONJ is a recognized adverse effect of bisphosphonates, with a plausible mechanistic pathway and epidemiological data showing increased risk with longer use. However, the low absolute risk and the fact that ONJ can occur spontaneously or with other risk factors mean that individual cases require careful assessment. Discontinuation of Fosamax may lead to symptom relief, and rechallenge can cause recurrence, further supporting a causal role. In safety-communication contexts, healthcare providers should inform patients about the risk of ONJ, especially before invasive dental procedures, and consider the duration of bisphosphonate therapy. The FDA-approved labeling advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The optimal duration of Fosamax use has not been determined, and for patients at low-risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This aligns with the observed risk increase after 2-3 years of treatment. In summary, the evidence from FDA-approved labeling and epidemiological studies demonstrates a causal association between Fosamax use and ONJ, with risk increasing with longer exposure. The absolute risk is low, but clinicians should remain vigilant, particularly in patients with additional risk factors such as dental procedures or cancer therapies. The mechanistic understanding of jawbone-specific responses to bisphosphonates supports this association, and clinical management should include risk assessment, patient education, and consideration of drug discontinuation when appropriate.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified medical contexts for case-specific decisions.

Frequently Asked Questions

What is the link between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that can cause osteonecrosis of the jaw (ONJ) as a recognized adverse effect. The drug inhibits osteoclast-mediated bone resorption, suppressing normal bone turnover and impairing healing after dental trauma or infection, leading to avascular necrosis. Epidemiological studies show increased risk with longer exposure, with a threefold increase after 2-3 years and eightfold after 10 years compared to past use (https://pubmed.ncbi.nlm.nih.gov/39400702/).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, dental implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures). The risk increases with duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How is ONJ diagnosed and managed in patients on Fosamax?

ONJ diagnosis is based on clinical examination and imaging to identify exposed necrotic bone in the jaw, ruling out other causes. Management includes discontinuing bisphosphonate treatment, especially before invasive dental procedures, as this may reduce ONJ risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For low-risk patients, drug discontinuation after 3-5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an medical context-client relationship?

No. Submission requests an initial records screening only and does not create an medical context-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.